Lilly has been a global leader in the fight against Alzheimer’s for nearly 30 years. Today, Lilly has molecules and diagnostics in various stages of clinical development, including seven investigational compounds to treat Alzheimer’s and two diagnostics to help better diagnose it. Lilly is proud of the robust Alzheimer’s disease research pipeline it has built and we are honored to be a part of other leading, independent collaborations in the broader Alzheimer’s disease scientific community.